



A pioneering regenerative medicine
platform in ophthalmology and
tissue repair

CEO Address
Annual General Meeting

Cambium Bio Limited
ASX:CMB

26 November 2024



Disclaimer

Summary Information

This Presentation contains summary information about the current activities of Cambium Bio Limited (ASX:CMB) ("Cambium Bio" or "the Company") as at the date of this Presentation. The information is of a general nature and does not purport to be complete or contain all information that an investor should consider when making an investment decision. This Presentation should be read in conjunction with Cambium Bio's other periodic and continuous disclosure announcements lodged with the ASX, available at www.asx.com.au.

Not an Offer

This Presentation is for information purposes only and is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or any other law. It is not and should not be considered an offer or an invitation to acquire shares or any other financial products in Cambium Bio.

Not Financial Product Advice

This Presentation does not constitute financial product or investment advice (nor tax, accounting or legal advice) and is not a recommendation to acquire shares in Cambium Bio. It has been prepared without taking into account the objectives, financial situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek professional advice.

Financial Data

All dollar values are in Australian dollars (A\$, \$, or AUD), unless otherwise stated. Any pro forma financial information is provided for illustrative purposes only and is not represented as being indicative of Cambium Bio's future financial performance.

Future Performance

This Presentation contains certain "forward-looking statements". These statements are based on current expectations, estimates and projections about Cambium Bio's business and the industry in which it operates, and management's beliefs and assumptions. Forward-looking statements can generally be identified by the use of forward-looking words such as "anticipate", "believe", "expect", "project", "forecast", "estimate", "likely", "intend", "should", "could", "may", "target", "plan" and other similar expressions. Such statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of Cambium Bio.

Investment Risks

An investment in Cambium Bio shares is subject to investment and other known and unknown risks, some of which are beyond the control of Cambium Bio. The Company does not guarantee any particular rate of return or the performance of the Company, nor does it guarantee the repayment of capital or any particular tax treatment.

Disclaimer of Liability

To the maximum extent permitted by law, Cambium Bio and its officers, employees, and advisers disclaim and exclude all liability for any expenses, losses, damages or costs incurred by you as a result of your participation in any investment in the Company or the information in this Presentation being inaccurate or incomplete in any way. Cambium Bio makes no representation or warranty, express or implied, as to the accuracy, reliability or completeness of information in this Presentation.

The information in this Presentation remains subject to change without notice. Cambium Bio reserves the right to withdraw or vary any part of this Presentation without notice.


FY24 Transformative Year for Cambium Bio



Successfully closed strategic merger with Cambium Medical Technologies, LLC in April 2024



Strengthened balance sheet with A\$3.48M strategic placement from key investors



Share consolidation completed to optimize capital structure



Enhanced corporate governance and operational capabilities

Strengthened Leadership Team

Integrated Executive Team



Dr Edmund Waller, MD, PhD
Chief Scientific Officer



Karolis Rosickas, MS, MBA
Chief Executive Officer



Terence Walts, MBA
Senior Advisor



Dr Neera Jagirdar, MD, MPH
VP, Clinical Development



Dennis Hannigan, MS
VP, CMC and Quality



Dr Louis Tong, MD, PhD
Scientific Advisor

Strengthened Leadership Team

Enhanced Board of Directors



Dr Edmund Waller, MD, PhD
Executive Director



Terence Walts, MBA
Executive Director



Dr Chandra Bala, MD, PhD
Non-Executive Director



Dr Sebastian Tseng, DDS, MBA
Non-Executive Director
ZYBT



Dr Chi-Tai Chang, PhD
Non-Executive Director
Orient Euro Pharma



Barry Sechos
Non-Executive Chairman

Advancing Elate Ocular[®] Towards Phase 3

Key development milestones

- FDA IND amendments in preparation
- Advanced CMC development with European CDMO partner
- Bioactivity and potency assay development progressing well
- Site selection and protocol optimization with global CROs
- Fast Track designation application submitted to FDA



Proteins
Growth factors
Vitamins
Antioxidants
Electrolytes

Strategic Outlook

Key activities and near-term catalysts

- Phase 3 trial initiation planned for April 2025, subject to additional financing
- Multi-centre studies across US, Australia, and Taiwan
- Licensing and M&A discussions with Big Pharma to commence after First Patient In (FPI)
- Phase 3 topline data expected mid-2026
- Capital raising activities underway with strong interest from potential investors



Contact details

Karolis Rosickas
Chief Executive Officer
kr@cambium.bio
+65-98112075
+61-404626029

Cambium Bio Limited

www.cambium.bio
1 300 995 098
ABN 13 127 035 358
16 Goodhope Street, Paddington
NSW 2021, Australia